CEO Executive AssistantBusiness Development as a Core Strategic Function
In pharmaceutical and biotech companies, business development is not a support function. It is one of the primary mechanisms through which you build pipeline, access technology, expand geographic reach, and accelerate the programs that internal R&D alone cannot advance fast enough. For a pharma CEO, the quality of your business development operation directly determines the strategic options available to your organization over the next five to ten years.
This guide is written for pharma CEOs who want to build a business development function that operates with the discipline, speed, and strategic clarity that the industry demands. The focus is on operational frameworks, team structure, deal process design, and the KPIs that tell you whether your BD operation is creating or destroying value.
The CEO’s Strategic Role in Business Development
You cannot delegate the strategy of business development. You can delegate execution, and you should, but the fundamental questions of where to grow, what capabilities to acquire, and what partnerships to prioritize are CEO-level decisions that need to be grounded in a clear view of where your pipeline, platform, and commercial ambitions are heading.
Before your BD team can operate effectively, you need to give them a clear mandate. That mandate should define your therapeutic area focus and whether you are expanding or deepening it, your pipeline stage preferences (early-stage assets versus late-stage, risk-adjusted value calculations), your deal structure preferences (licensing versus collaboration versus acquisition), your geographic strategy (domestic focus, specific ex-US markets), and your financial parameters for deal pursuit.
A BD team without a clear mandate will pursue whatever opportunities come inbound, which produces a scattered portfolio of deals that collectively do not advance your strategy. Your job as CEO is to make the mandate explicit, revisit it regularly, and hold your BD leadership accountable for pursuing deals that fit within it.
Setting Deal Thresholds and Decision Rights
One of the most important structural decisions in BD operations is defining who has authority to make which decisions at which deal stages. A clear decision rights framework prevents two common failure modes: BD teams that move too slowly because every preliminary conversation requires CEO approval, and BD teams that over-invest in deals that do not fit strategy because no one is checking alignment early enough.
A workable framework defines preliminary outreach and NDA execution as BD team authority, term sheet negotiation as BD leadership authority with CEO awareness, and signed agreements above defined financial thresholds as requiring CEO or board approval. The specific thresholds will vary by organization, but the principle of tiered decision rights with appropriate escalation points is universal.
Structuring the Business Development Team
Pharmaceutical business development requires a combination of scientific fluency, deal-structuring capability, relationship management skill, and market intelligence expertise. These rarely exist in a single person, which is why the structure of your BD team matters as much as the talent within it.
Core Team Roles
A mature pharma BD function typically includes a Chief Business Officer or Head of Business Development at the leadership level, responsible for setting the BD strategy, managing the most important external relationships, and representing BD in executive and board discussions.
Deal leads or BD Directors manage individual transactions through the full lifecycle from initial assessment through negotiation and close. They need both scientific literacy (enough to evaluate assets and understand technical risk) and deal mechanics experience (term sheets, licensing structures, collaboration agreements).
An alliance management function, sometimes integrated into BD and sometimes separate, is responsible for the health and performance of existing partnerships. This is a distinct skill set from deal origination and should not be treated as a secondary responsibility for deal leads who are focused on new transactions.
Business intelligence or competitive intelligence capability, whether a dedicated role or a shared function, ensures that your BD team is making decisions based on current market data rather than dated assumptions about competitive positioning, deal terms, and therapeutic area dynamics.
Building the Scientific Interface
One of the most common structural weaknesses in pharma BD operations is poor integration with internal R&D. When BD and R&D operate as separate functions with limited communication, BD teams pursue deals that do not fit internal capabilities, and R&D teams do not provide timely, useful input on external assets.
Establish a formal BD-R&D interface through a scientific advisory process or a designated R&D liaison for BD evaluations. Every asset assessment should include a structured scientific review that produces a clear recommendation with supporting rationale, delivered within a defined timeframe. If your scientific review process takes longer than four weeks for a preliminary assessment, you will consistently lose deals to faster competitors.
The Deal Process Framework
A well-designed deal process moves potential transactions through defined stages with clear criteria for progression, defined ownership at each stage, and structured decision points that prevent deals from either dying in the pipeline unnecessarily or advancing further than their strategic fit warrants.
Stage 1: Origination and Triage
Deal origination comes from multiple sources: inbound approaches from partners and licensors, active outreach based on intelligence about assets in development, conference and networking activity, and scientific publication monitoring. Your BD team should have a systematic approach to each channel rather than relying primarily on inbound deals.
Triage is the process of rapidly assessing whether an opportunity warrants investment of further BD resources. A good triage framework evaluates strategic fit (does this align with our mandate?), scientific plausibility (is the underlying science credible?), asset stage and data package quality, competitive positioning in the relevant indication, and preliminary financial feasibility. This assessment should be completable within one to two weeks based on publicly available information plus an initial confidential discussion.
Stage 2: Preliminary Assessment
Deals that clear triage move into a more detailed assessment phase, typically under a mutual confidentiality agreement. This phase involves a deep scientific review by internal R&D, a commercial assessment of the target indication and market opportunity, a preliminary IP review, and an initial valuation framework.
The output of preliminary assessment is a recommendation on whether to pursue the deal and, if so, with what deal structure and parameters. This recommendation goes to BD leadership and, for significant opportunities, to the CEO.
Stage 3: Term Sheet Development and Negotiation
Once a decision is made to pursue a deal, BD leads the development of a term sheet that reflects your organization’s deal objectives and financial parameters. This phase involves active negotiation with the counterparty, legal review of deal structure, finance involvement in deal modeling and valuation, and executive alignment on key terms.
Term sheet negotiation is where deal speed becomes critical. Pharma BD is competitive, and counterparties will often advance parallel conversations with multiple potential partners. Your team’s ability to move quickly from term sheet to agreed terms is a meaningful competitive advantage.
Stage 4: Due Diligence and Definitive Agreement
Full due diligence runs in parallel with drafting the definitive agreement. Due diligence scope varies by deal type but typically includes scientific and clinical due diligence (led by R&D), IP due diligence, regulatory due diligence, commercial due diligence, and financial due diligence.
Project management discipline during due diligence is essential. Establish a due diligence project lead, use a shared data room and tracker, and set clear timelines with milestones. Due diligence processes that drag on for months signal organizational dysfunction to your counterparty and create deal fatigue that kills transactions that should close.
Stage 5: Alliance Launch and Management
Closing a deal is not the end of the BD team’s work. The first 90 days of a new partnership are critical for establishing the governance structures, communication cadences, and working relationships that determine whether the alliance delivers on its promise.
Establish a joint steering committee or equivalent governance structure with clear meeting frequency and decision-making authority. Designate alliance managers on both sides with explicit responsibility for partnership health. Document key performance obligations and timelines in a joint project plan. These structural elements, put in place at alliance launch, prevent the misalignments and communication breakdowns that cause many pharma partnerships to underdeliver.
KPIs for Business Development Operations
Measuring business development performance requires metrics across the deal pipeline, deal execution, and alliance performance dimensions.
Pipeline Metrics
Pipeline opportunity count and value tracks the number of deals under active assessment and their estimated peak sales potential or strategic value. This tells you whether your origination activity is sufficient to meet your deal volume targets.
Triage conversion rate measures the percentage of triaged opportunities that advance to preliminary assessment. A very low rate may indicate poor origination quality; a very high rate may indicate insufficient triage rigor.
Deal progression velocity tracks average time from initial contact to term sheet and from term sheet to close. Benchmarking these numbers against industry norms identifies where your process has friction.
Deal Quality Metrics
Strategic alignment score is a structured assessment of how well each closed deal aligns with the stated BD mandate. This metric holds your team accountable for pursuing strategy rather than opportunistically closing deals.
Post-close value realization tracks whether deals deliver the value projected in the business case. Regularly reviewing deals against their original projections builds organizational learning and improves future deal assessment discipline.
Alliance Performance Metrics
Milestone achievement rate tracks the percentage of contractual milestones met on time across your active alliance portfolio. A declining rate is an early warning signal for portfolio execution problems.
Alliance health scores are periodic qualitative assessments of relationship quality, communication effectiveness, and joint team function across your partner portfolio. Governance problems that are not captured in milestone data often surface first in qualitative alliance reviews.
Competitive Intelligence and Market Positioning
Your BD team needs current, structured intelligence about the deals your competitors are doing, the assets available in your therapeutic areas, the valuation norms for the deal types you pursue, and the emerging science that is shaping the competitive landscape.
Establish a competitive intelligence process that includes regular review of deal announcements and filings, systematic monitoring of clinical trial registrations and scientific publications, conference coverage protocols, and a structured format for intelligence reports that go to BD leadership and the CEO.
Intelligence gathered through the BD process itself, including insights from counterparty conversations, is also valuable and should be documented systematically. Your CRM or deal tracking system should capture not just deal outcomes but the intelligence gathered during deal processes, including assets that are available but not currently a fit, pricing signals from competitive discussions, and intelligence about counterparty priorities and constraints.
For how business development connects to your broader commercial strategy and revenue planning, see our guide on pharma commercial operations. For context on how BD fits within your overall organizational framework, the pharma operations guide provides a comprehensive view.
External Relationship Infrastructure
The best BD opportunities often come from relationships that your team has cultivated over years, not from cold outreach or conference encounters. Building a systematic approach to relationship development with key external stakeholders, including potential partners, academics, venture firms, and investment bankers in the pharma space, is a long-term investment that pays dividends in deal quality and deal flow.
As CEO, your external relationships are a strategic asset. The partnerships you can access directly, the credibility your leadership brings to a counterparty’s assessment of your organization, and the signals you can send about your organization’s direction through your own external presence all contribute to your BD team’s effectiveness. The most successful pharma BD functions treat the CEO as a relationship resource and deploy that resource strategically in the deals where it matters most.
According to the Deloitte 2024 Life Sciences M&A and Partnering Report, the deals that create the most durable value in pharma are those grounded in genuine scientific alignment between partners, not just financial engineering. That finding reinforces what experienced BD leaders already know: the best deals start with relationships built on mutual respect for each other’s science, strategy, and organizational capabilities.
Related Reading
For further context, explore Pharma CEO Guide to Business Operations Management and Pharma CEO Guide to Clinical Operations Management.